APA (7th ed.) Citation

G, B., J, T., A, R., J, J., A, Z., M, K., . . . JS, S. (2025). Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis. Clinical drug investigation, 45(8), 551. https://doi.org/10.1007/s40261-025-01453-8

Chicago Style (17th ed.) Citation

G, Burmester, et al. "Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis." Clinical Drug Investigation 45, no. 8 (2025): 551. https://doi.org/10.1007/s40261-025-01453-8.

MLA (9th ed.) Citation

G, Burmester, et al. "Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis." Clinical Drug Investigation, vol. 45, no. 8, 2025, p. 551, https://doi.org/10.1007/s40261-025-01453-8.